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In recent  years,  the  ofﬁcial  regulation  of  chemicals  and  chemical  products  has  been  intensiﬁed.  Explicitly
for  spray  products  enhanced  requirements  to  assess  the consumers’/professionals’  exposure  to  such
product  type  have  been  introduced.
In this regard  the  Aerosol-Dispensers-Directive  (75/324/EEC) with  obligation  for  marketing  aerosol  dis-
pensers,  and  the  Cosmetic-Products-Regulation  (1223/2009/EC) which  obliges  the  insurance  of  a  safety
assessment,  have  to be  mentioned.  Both  enactments,  similar  to the REACH  regulation  (1907/2006/EC),
require  a robust  chemical  safety  assessment.  From  such  assessment,  appropriate  risk  management  meas-
ures  may  be identiﬁed  to adequately  control  the  risk  of  these  chemicals/products  to  human  health  and
the environment  when  used.
Currently,  the  above-mentioned  regulations  lack  the  guidance  on  which  data  are  needed  for  preparing
a  proper  hazard  analysis  and  safety  assessment  of spray  products.
Mandatory  in  the process  of  inhalation  risk and  safety  assessment  is  the  determination  and  quantiﬁ-
cation  of the  actual  exposure  to the  spray  product  and  more  speciﬁcally,  its ingredients.  In this  respect
the  current  article,  prepared  by  the  European  Aerosol  Federation  (FEA,  Brussels)  task  force  “Inhalation
Toxicology”,  intends  to introduce  toxicological  principles  and  the  state  of  the  art  in currently  available
exposure  models  adapted  for typical  application  scenarios.  This  review  on  current  methodologies  is
intended  to guide  safety  assessors  to  better  estimate  inhalation  exposure  by using  the  most  relevant
data.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
The human respiratory tract is a dynamic system responsible
or the gas exchange and the ﬁltering of airborne pathogens and
oreign material (Salem and Katz, 2006).
To understand the speciﬁc defence mechanisms and ﬁlter func-
ion of the respiratory tract, some anatomical basics are introduced.
he vestibular hairs in the nose, mucociliary clearance, and high-
elocity clearance/reﬂex mechanisms (sneezing and coughing) are
rst mechanisms of such defence. Additional, non-ciliated airway
ecretions, blood/lymph clearance, immunological responses, con-
ribute to this protective function.
As illustrated in Fig. 1, particle/droplet deposition throughout
he respiratory tract is determined by the inhalation character-
stics (duration, frequency, and strength), the size (aerodynamic
iameter) of sprayed particles/droplets and their physicochemical
roperties and speciﬁc clearance mechanisms.
Particles/droplets exceeding a diameter of 30 m are normally
ltered in the nasopharyngeal passage and would not reach the
ung. In contrast, smaller ones may  reach the lower airways. The
ucosal lining of the upper respiratory tract can serve as a pro-
ective barrier and a trap for such smaller particles/droplets. The
ucociliary escalator, which promotes the movement of mucosal
uid up the extrathoracic region (nose, mouth and throat) plays a
ajor role in the clearance process of inhaled material.
The German MAK  Commission stated that the particles/droplets
ith an aerodynamic diameter of >15 m are deposited almost
xclusively in the extrathoracic region, and healthy humans
ill clear particles >7 m within 24 h from the tracheobronchial
ompartment. The threshold of particle/droplet diameters small
nough to reach the alveoli is often set to be 5 m (MAK, 2012).
owever, in this document particles/droplets with an aerodynamic
iameter <10 m are conservatively considered to be respirable
nd suspected to reach the deeper lung.
Beside the mentioned deposition of particles/droplets propel-
ants (gases) and solvents (vapours), often used in spray products,
ould have an additional health impact which has to be taken into
ccount for the overall hazard assessment of inhalable chemicals
nd products.
. AimsThis article is intended to introduce important elements for the
nhalation safety assessment, to enable safe use of spray products
n both occupational and consumer settings, and help improve the . . . .  .  . .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  .  . . .  . . . .  . .  .  .  . . . .  .  .  . . . . .  . . .  .  .  .  . . . .  .  . . . . .  48
understanding of relevant inhalation exposure scenarios in typ-
ical application environments. Product-type speciﬁc approaches
for modelling the inhalation exposure of spray products will be
reviewed.
A tiered (step-wise) approach for preparing a robust safety
assessment is recommended, why  detailed information on the
ingredients hazard, the spray characteristics and data on the
explicit exposure is needed. Both, local effects in the respiratory
tract and the systemic inhalation toxicity have to be taken into
account for the acute and repeated exposure.
It is essential to understand the realistic occupational or con-
sumer exposure and application habits, in order to estimate the
impact of other possible routes (such as dermal, oral and/or envi-
ronmental background exposure) on the total systemic exposure
and body burden.
3. Principles of the inhalation safety assessment
Four key elements have to be addressed:
3.1. Data collection
Available safety data for all ingredients and their speciﬁc regu-
lation have to be evaluated.
3.2. Hazard assessment
The hazard assessment is processed in hazard identiﬁcation and
hazard characterization. Within hazard identiﬁcation, ingredients
are identiﬁed which are suspected to cause health concern when
inhaled. For hazard characterization, the level of exposure due to
the speciﬁc content of certain chemicals in the spray product is
considered.
With this information, a decision should be made on the need
of an explicit exposure assessment. If no hazardous chemicals are
used in the spray product, or if they are only present at negligi-
ble, low concentrations, a risk characterization without an explicit
exposure assessment could be sufﬁcient.
3.3. Exposure assessmentTo get knowledge on the realistic inhalation exposure to iden-
tiﬁed hazardous ingredients data on the room size in which the
individual is present during spraying, and details on the spray appli-
cation, e.g. frequency, duration and direction is needed. With one
W.  Steiling et al. / Toxicology Letters 227 (2014) 41–49 43
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knowledge on basic toxicological hazards. Additional data sources
for the safety assessment could be found in related toxicological
reports, ofﬁcial data ﬁles, safety studies, peer-reviewed articles, and
opinions by regulatory bodies.
Hazard Ass essment
(system ic / lo cal toxicity)
Avail abl e Data  on  each In gredi ent
(re gulaons : prohibion , max.  con c., ph ys.-ch em.  da ta)
Hazard Iden ﬁcaon
Hazard Cha rac ter iza on
Risk  Character izao n
Concent raon  in Spr ay Produc t
Expo sure Ass essme nt
Exposure
Modeling
(e.g. 1- or 2-box models)
Realisc Exposure
Measurement
(under simulated use
condions)
Characteri zaon  of  the sp ray
Screening  Ass ess mentFig. 1. Leading terms with
f the following options a more sufﬁcient exposure estimate could
e reached:
Screening assessment as worst-case exposure.
Progressively more complex exposure modelling.
Measuring the actual amount of spray inhaled, or potentially
inhaled by simulating the realistic exposure scenario.
It is important to note that the ﬁnal exposure is determined by
he particle size and the distribution of particles/droplets in the
xposure room under use conditions. The composition of the for-
ulation and the technical details of the spray can (e.g. nozzle, size,
ropellant type) are of signiﬁcant impact.
.4. Risk characterization
Modelled or measured human inhalation exposure data has to
e compared with suitable derived threshold values of no concern.
In case of an unfavourable risk characterization, there is a need
o further reﬁne the exposure assessment (e.g. using a more real-
stic approach), technically modify the spray characteristics, or to
eformulate the product.
Fig. 2 illustrates the basic principles of this tiered safety assess-
ent of spray products.
It is important to keep in mind that techniques and ter-
inology used in the safety assessment should be checked
or their compliance with relevant legislation and ofﬁcial guid-
nce.
. Inhalation safety assessment in detail
.1. Data collection
It is recommended to start a safety assessment of spray products
ith the acquisition of available hazard data of individual ingredi-
nts and the understanding of their speciﬁc content in the spray
roduct.
The hazard identiﬁcation of individual ingredients typically
tarts with the information given in related material safety data
heets (MSDS). Especially the toxicological classiﬁcation according
o the Globally Harmonized System of Classiﬁcation and Labelling
f Chemicals (GHS)/EU Classiﬁcation, Labelling and Packaging
egulation (1272/2008/EC, CLP) could be a starting point to get human respiratory tract.Fig. 2. Tired approach for the Inhalation Safety Assessment (SCCS, 2012). Colour
code in boxes: Blue related to ingredients. Yellow related to product exposure. (For
interpretation of the references to color in ﬁgure legend, the reader is referred to
the web  version of the article.)
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.2. Hazard assessment
.2.1. Hazard identiﬁcation
With the mentioned data collection a useful understanding
f the principle toxicological properties of the related chemicals
ould be reached, but for a scientiﬁcally robust safety assessment,
etailed information on the following toxicological endpoints may
e needed:
Acute systemic toxicity after oral, dermal or inhalation exposure.
Irritation/corrosion (local effects) after mucosal, dermal and/or
inhalation exposure.
Dermal and respiratory sensitization.
Mutagenic/genotoxic potential.
Repeated dose toxicity (e.g. 28-day/90-day studies) when
orally, or topically exposed, or when inhaled, with the
corresponding thresholds identiﬁed: No-Observed-Adverse-
Effect-Level (NOAEL)/No-Observed-Effect-Level (NOEL), or No-
Observed-Adverse-Effect-Concentration (NOAEC)/No-Observed-
Effect-Concentration (NOEC).
Reproductive/developmental toxicity (maternal/foetal).
The reliability and robustness of the ﬁnal hazard identiﬁcation
s related to the quality of individual information used (Schneider
t al., 2009), why the most robust studies should be preferred, ide-
lly those directly related to inhalation (e.g. OECD testing guideline
412 or #413).
In case inhalation data are lacking, this data gap might be
ridged by other appropriate toxicological information in a Weight
f Evidence approach (WoE). In this approach e.g. robust oral
oxicity data, may  function as an adequate surrogate with a route-
o-route extrapolation as described in the European Chemicals
gency (ECHA) guidance (ECHA, 2012a).
.2.2. Hazard characterization
For the hazard characterization all compiled toxicity data, sys-
emic as well as local ones, have to be considered and determined
y adequate dose descriptors like [mg/kg bw/day] for systemic
nd [mg/cm2 lung surface area] or [mg/g lung weight] for local
ffects. Usually these descriptors are expressed as a NOAEC (for
ocal and systemic effects) or LC50 (acute lethal concentration),
espectively.
Once the overall hazard has been determined for the individ-
al ingredients, its health impact during product inhalation can
e estimated related to their individual content. The likelihood
f reactivity between individual ingredients should be consid-
red.
In cases where the content of certain ingredients is very low
n Exposure-Based-Waiving (EBW) approach could be applied
Carthew et al., 2009) as a justiﬁcation for concluding that there is
o risk. The application of such approach requires expert knowl-
dge and a detailed understanding about its restrictions and
imitations.
.3. Exposure assessment
Spray products have a wide variety of applications and the actual
ealth related risk to humans (workers, professionals, consumers)
epends on the hazard and exposure to the sprayed chemicals at
peciﬁed use conditions. Therefore, a proper exposure assessment
s crucial and should be based on detailed knowledge of the use
onditions established from data on habits and practices.
Generally, the exposure to inhalable substances is determined
y:etters 227 (2014) 41–49
Spray can Size
Pressurizing system (propellant driven spray, pump
spray)
Geometry of the spray container (volume) and the
nozzle
Content delivery
Spray formulation Qualitative/quantitative composition
Propellant and solvents used
Application format e.g. foam, mousse, jet, ﬁne spray,
coarse spray
Spray usage Frequency
Duration
Product release per application/time
Spraying jet
Spray direction (e.g. towards or away from the body)
Exposure situation Application type (consumer, industrial/professional)
Particle/droplet size distribution at spraying and its
maturation
Duration of stay in spray environment
Room volume and temperature
Ventilation rate (air exchange)
Activity level of the exposed individual (e.g. moving,
resting)
For practical reasons only those data, which are expected to have
a relevant impact on the speciﬁc exposure have to be taken into
account.
4.3.1. Screening approach
ECHA has published some guidance for the exposure estimation
to spray products (ECHA, 2012b). For screening purposes, a rough
estimate of the exposure to a certain sprayed product/chemical
could be sufﬁcient or even appropriate. In such ﬁrst screening
assessment, it is assumed that exposure is to a certain ingredi-
ent quantity which released the dispenser instantaneously. An
immediate homogenous distribution in a ﬁxed exposure room is
assumed.
Concentration (exposure)
= weight of ingredient in the released spray formulation [mg]
room volume [m3]
(1)
This conservative approach will provide overestimated expo-
sure for volatile substances (ﬁxed room volume without air
exchange), but will underestimate short-term local exposure
for particles/droplets (inhomogeneous distribution shortly after
spraying) as the sprayed formulation needs a while to become
homogeneously distributed in the room.
The distribution/exposure scenario has to be representative for
the speciﬁc product type. For cosmetic and personal care products,
which are sprayed towards the body, it is assumed that the total
amount of the sprayed product enters immediately and homoge-
nously the “personal zone”/“breathing zone”, of about 2 m3.
For many hazardous ingredients in spray products such simple
exposure assessment may  be appropriate to prepare a reliable risk
characterization.
4.3.2. Exposure Modelling
Based on the diversity of spray products and their variability
in applications, a number of models for a more realistic exposure
assessment, varying in complexity, have been developed and are
in use. An understanding of certain individual strengths and weak-
nesses of these models is needed for a proper choice.
For a robust exposure assessment the amount of sprayed prod-
uct/chemical in a given time and realistic room conditions should
be taken into account. The initial air concentration, dilution by
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Although the air concentration will be higher in Box A, total
exposure will depend on the residency time in each box. The
amount of material which could be inhaled is determined by its con-
centration in individual boxes, the speciﬁc residency times and the
Box A
Box B
Fresh air Exhaust airW.  Steiling et al. / Toxico
entilation and sedimentation are additional important param-
ters to describe the ‘real use’ conditions. In this regard, the
ime-Weighted-Average concentration (TWA) expresses the time-
ependent change of product concentration in the exposure room
fter spraying.
Typical spraying values of some common consumer products are
iven in the following tables (Tables 1–3), however, some of these
arameters are triggered by individual habits and any two  people
ay  use the same product type differently (Steiling et al., 2012).
o build realistic exposure scenarios it is therefore important to
nderstand how spray products are realistically used (Table 1).
able 1
ischarge rates (including propellants and solvents) and typical spray times for
ome consumer products.
Consumer product Discharge rate (g/s) Spray time (s)
Hairspraya 0.7 3–4
Antiperspirant/deodorant spray (90th
percentile)
0.8c 1.4d
Air freshenera 1.5–1.8 4–5
Furniture polisha 1.8 2–3
All-purpose cleaning spray 1.2e 24e
Starcha 2.0 2–3
Carpet cleanera 2.0 20–30
Oven cleanera 2.0 10–15
Flying insect killerb 1.5 10
Crawling insect killerb 1.5 60–90
De-icera 2.5 15–20
Paintsa 0.8 30–40
a BAMA (2008).
b Bremmer (2006).
c Bremmer et al. (2006).
d Steiling et al. (2012).
e Weerdesteijn et al. (1999).
Values for the daily applied amounts and the application fre-
uency of some cosmetic products are given in Table 2. The amount
er application represents the total amount of product including
he related propellant and solvent content (can weight loss), but
ot the quantity of product landing on the skin or hair, which is
uch lower (Steiling et al., 2012).
able 2
osmetic spray products: amounts (including propellants and solvents) applied and
requency of use.
Product application Amount/day (g) Frequency of
application/day
Reference
Deodorant
(aerosol)
6.1 (90th
percentile)
2 McNamara et al.
(2007) and Hall
et al. (2007)
Hairspray (aerosol) 6.8 (75th
percentile)
1 Bremmer (2006)
Hairspray (pump
spray)
3.6 1 Loretz et al. (2006)
Typical exposure data of some household aerosol products are
iven in Table 3.
able 3
xposure time of some sprayed household products (US-EPA, 2011).
Products Mean spraying duration
per use (min)
90th percentile
Spray shoe polish 7.49 18
Aerosol spray paint 39.54 60
Aerosol rust remover 18.57 60
Aerosol spray paints for cars 42.77 120
Spray lubricant for cars 9.90 15tters 227 (2014) 41–49 45
Beside the aforementioned conservative exposure calculation,
using standard values of well designed surveys and speciﬁc studies
on typical application/use habits, several computational exposure
models have been developed in parallel.
Such computer programmes, developed to calculate the
expected inhalation exposure varies from simple ones to sophisti-
cated models. Later takes into account various factors to determine
most realistically how much of a spray/chemical is actually inhaled,
exhaled, is reaching deeper lung are or is deposited. Currently, the
following models have been established with preferred application
to certain exposure scenarios:
a) BAMA/FEA Indoor Air model (one-box).
) RIVM ConsExpo 4.1 models (one-box).
c) BAuA SprayExpo 2.0 model (one-box).
) RIFM 2-Box Indoor Air Dispersion model (two-box).
e) RIFM Computational Fluid Dynamics (CFD) and Multiple Path
Particle Deposition (MPPD) model.
The most obvious differences between these models are the
number of assumed exposure rooms (boxes). Some are utilizing
a single exposure room, others use two  or more zones/rooms.
4.3.2.1. One-box models. The one-box model (Fig. 3) is based on the
assumption that particles/droplets are homogeneously distributed
in an exposure room of known volume. Concentrations are calcu-
lated as a function of the sprayed amount, the room volume and
the ventilation rate as well as the time elapsed from the start of the
emission and staying in this room.
In
Out
Later Expos ureEarly Exposure
Fig. 3. Theoretical behaviour of a sprayed product in a room.
4.3.2.2. Two-box models. A more sophisticated approach is the
two-box model, which assumes 2 different zones/rooms (Box A
and Box B) in which the emitted material is homogeneously dis-
persed as illustrated in Fig. 4. This scenario automatically results in
two separate exposure environments which have to be taken into
account when calculating the overall exposure.source
Fig. 4. Principles of a two-box model (far ﬁeld; spray directed away from the body).
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Table 4
Consumer exposure models for spray products.
Exposure model Products for which the model is useful
BAMA/FEA Indoor Air model
(one-box)
Products sprayed into the air (e.g. air
freshener)
Products sprayed onto a horizontal
surface (e.g. carpet cleaner)
RIVM ConsExpo 4.1 model
(one-box) (RIVM, 2007)
Products sprayed into the air (e.g. air
freshener)
Products sprayed at the body (e.g.
cosmetic products)
Products sprayed at a vertical surface
(e.g. paints)
Products sprayed on to a horizontal
surface (e.g. carpet cleaner)
BAuA SprayExpo 2.0 model
(one-box)
Products sprayed into the air (e.g. air
freshener)
Products sprayed towards a surface
(e.g. paints)
RIFM 2-Boxes Indoor Air
Dispersion model (two-boxes)
Products sprayed into the air (e.g. air
freshener)
Products sprayed at the body (e.g.
cosmetic products)
Products that are combustible
(candles)
Products that are passive or heated
diffusers
RIFM Computational-Fluid-
Dynamics (CFD) and MPPD
model
Products sprayed into the air (e.g. air
freshener)
Products sprayed at the body (e.g.
cosmetic products)
Products sprayed at a vertical surface
(e.g. paints)
Products sprayed on to a horizontalFig. 5. Near ﬁeld/far ﬁeld exposure with products sprayed towards the body.
hysiological minute ventilation (breathing frequency multiplied
ith the depth of ventilation) of the exposed individual.
For products directed towards the body, e.g. hairspray, the two-
ox model can be divided in a short term “near ﬁeld” exposure (e.g.
 min  in 2 m3) and a longer “far ﬁeld” scenario (e.g. 18 min  in 10 m3)
Rothe et al., 2011). In this case, Box A stands for the breathing
one and Box B for the rest of the room (e.g. a smaller bathroom)
Fig. 5).
.3.2.3. Multiple path particle deposition model. The Multiple Path
article Deposition (MPPD) model is a higher tier exposure assess-
ent model utilizing a computational model of human and rat
peciﬁc anatomical differences in the respiratory tract (the nasal
avity and lung airways). The MPPD allows the direct extrapola-
ion of laboratory animal data to human exposure and is capable
o estimate dose-related kinetics of inhaled material (Schroeter
nd Kimbell, 2006a,b; Martonen and Schroeter, 2003; Garcia and
imbell, 2009; Schroeter, 2009). The MPPD model allows the spe-
iﬁc determination of the dose deposited at various sites of the
espiratory tract, and to calculate the dose which can be systemi-
ally up taken across the tissue surface in the lung. The correct
uantiﬁcation of the deposited/penetrated amount of material
equires the use of respiratory or at least dermal penetration
oefﬁcients and sufﬁcient knowledge on physicochemical charac-
eristics of the individual chemical.
During the last couple of years, some of these models became
ublicly available such as the BAMA/FEA Indoor Air Model,
IVM ConsExpo 4.1, SprayExpo (Koch et al., 2012) and BG-Spray
Eickmann, 2007) and found to beuseful for determining systemic
xposure. Model-speciﬁc advantages and drawbacks are described
n the literature (Eickmann et al., 2007).
The product-speciﬁc application of these models is summarized
n Table 4.
.3.2.4. Example for using the one-box model. To better understand
he various exposure modelling methods discussed, an example is
iven for calculating the user’s exposure to a hypothetical spray
ir freshener (AF) with ingredient “A” (chemical of interest) for-
ulated at a content of 0.5%. Following the content of Table. 4, the
AMA/FEA Indoor Air model, a one-box model, should sufﬁce to
alculate exposure for such a scenario.
The typical spraying time for an AF is 5 s with a product release of
.5 g/s (BAMA, 2008). The room in which an AF is more commonly
prayed is the bathroom. A small bathroom has a volume of 10 m3
RIVM, 2006). For this scenario we also assume an adult with a
espiration rate of 13 L/min for light activity (Salem and Katz, 2006)
nd a body weight (bw) of 65 kg. If the person stays in this bathroom
or 30 min, the amount this person will be exposed to ingredient “A”
s calculated as follows:surface (e.g. carpet cleaner)
1. 1.5 g/s product release for 5 s spraying (1.5 g/s × 5 s) ends up in
7.5 g product released.
2. 0.5% of ingredient “A” in the air freshener (7.5 g × 0.005 = 0.037 g)
results in 37.5 mg.
3. Assuming this amount is homogenously distributed in 10 m3
bathroom, this gives an initial concentration of 0.00375 mg/L
[(37.5 mg/10 m3)/m3/1000 L].
4. Assuming no ventilation (i.e. “sealed room”), and a respi-
ration rate of 13 L/min (0.00375 mg/L × 13 L/min), comes to
0.04875 mg/min of inhaled substance “A”.
5. For the duration of 30 min  spent in the bathroom the
person will be exposed to (0.04875 mg/min × 30 min)
1.4625 mg  of substance “A” or 22.5 g/kg for a 65 kg person
(1.4625 mg/65 kg = 0.0225 mg/kg bw or 22.5 g/kg bw).
However when running the mentioned BAMA/FEA Indoor Air
model this worst-case exposure scenario will become more real-
istic by incorporating an air exchange of 2 times per hour, the
ventilation rate associated with a bathroom (RIVM, 2006). Tak-
ing this air exchange into consideration, a 30 min  time weighted
average bathroom concentration (30 min  TWA) for chemical “A” is
calculated to be 2.4 mg/m3. With this TWA  value, the modelling
calculates the 30 min  exposure to ingredient “A” to be 0.936 mg  or
14.4 g/kg bw (vs. 22.5 g/kg bw as calculated above). This reﬁne-
ment is more realistic than the previously calculated value, but
remains conservative, as other relevant information (such as par-
ticle size distribution) are not considered. Following the scheme
given in Fig. 1, for a robust risk assessment, the more details one
considers the more realistic will be the estimate of the respirable
fraction and ultimate local or systemic exposure to the substance
of interest.
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.3.3. Exposure measurement
For some applications and/or products computational mod-
lling data may  not give a sufﬁcient level of conﬁdence necessary to
e taken in the risk characterization. For exposure scenarios where
he spray is directed to men  (e.g. a hair spray) experimental mea-
urements of the respirable fraction of the spray into the ‘breathing
one’ of this individual may  be needed.
For such measurement it should be understood that parti-
le/droplet size could be dynamic due to the evaporation of e.g.
he solvent after releasing the spray container. During such mat-
ration of particle size larger particles/droplets become smaller
nd under speciﬁc conditions particles/droplets could become big-
er by aggregation (EAF, 2009). In either case, droplet size and
ensity directly affect their settling velocity and elimination from
he “breathing zone.” Product spray clouds are complex and their
escription is time-related and determined by e.g. the product com-
osition and geometry of the spraying dispenser. Currently, no
omputational modelling is available to conduct a sufﬁciently reli-
ble simulation of this particle/droplet maturation; this is why it is
ecessary to resort to measurement.
.3.3.1. Measurement of spray exposure under simulated use condi-
ions. Mannequins with simulated anatomical features, equipped
ith an aerosol sampler in the modelled upper respiratory tract are
roperly connected to a particle size spectrometer (Fig. 6), to mea-
ure the respirable dose, small enough to reach the deeper lung.
ndividual use conditions (adult, child) and habits and practices of
praying (frequency and duration) could be simulated with such
odel. The aerodynamic diameter and the number of individual
articles/droplets in a deﬁned volume per minute can be measured,
ven speciﬁcally in the ‘breathing zone’ over a certain time period.
he resulted particle size distribution data allows the extrapola-
ion of the respirable dose for that given formulation under that
pplication conditions (Carthew et al., 2002).In cases where spray products are not intentionally directed
owards men, a slightly different measurement procedure could
e useful. For such application the product has to be sprayed
nto a cabinet of deﬁned volume and an installed impactor will
Fig. 6. Mannequin with particle sizer spectrometer.tters 227 (2014) 41–49 47
collect speciﬁcally deﬁned airborne fraction on integrated ﬁlters
with deﬁned mesh-sizes. The respirable fraction deposited on the
corresponding impactor inlet is typically gravimetrically measured
or chemically analyzed.
4.4. Risk characterization
Once the exposure to the relevant spray fraction is reliably
understood, by estimation, modelling or measurements, the risk to
human health at that level of exposure can be reliably assessed.
For the ﬁnal risk characterization regulators often require their
speciﬁc safety factors and calculations for getting their accep-
tance. In this regard the most commonly used values for the risk
assessments of chemicals are the Margin-of-Safety (MoS) and the
Risk-Characterization-Ratio (RCR).
In a quantitative risk assessment it has to be decided if the iden-
tiﬁed hazards are linked to a certain threshold or not. A threshold
in this regard is deﬁned as a dose below which no statistically sig-
niﬁcant increase in adverse effects on the exposed organism can
be identiﬁed. Adverse effects without a threshold are for example
genotoxic carcinogens. A method developed by the Joint FAO/WHO
Expert Committee on Food Additives (JECFA) for assessing non-
threshold effects of genotoxic carcinogens (Barlow et al., 2006)
could be applied to characterize the risk of possibly unavoidable
non-threshold contaminants in sprays.
4.4.1. Risk-characterization-ratio (RCR)
Under REACH a risk assessment is part of a challenging pro-
cess which is known as a Chemical Safety Assessment (CSA). Details
how this has to be achieved and in particular, how to estimate e.g.
inhalation exposure is given in the ECHA IR/CSA guidance (ECHA,
2012b).
Important in such CSA risk assessment is the calculated RCR,
the ratio between the actual exposure and the estimated derived
no effect level (DNEL) for certain adverse effects. Thus, for a given
exposure to an individual ingredient the RCR is deﬁned by:
RCR = Exposure
DNEL
(2)
RCR values < 1 are interpreted as of no concern and risk reduc-
tion measures are not necessary. In cases of RCR > 1, a reﬁnement
of exposure is required or risk reduction measures are necessary
(e.g. modiﬁcation of the spray characteristics or reformulation of
the product) (ECHA, 2012a).
4.4.2. Margin of safety (MoS)
The MoS  is commonly deﬁned as a dimensionless number that
establishes the relationship between the dose of a certain chemical
necessary for a desired effect and the dose of the same chemical
resulting in an undesired effect. Such calculation is regularly used
in the safety assessment for e.g. drugs where a clear beneﬁcial or
effective dose can be distinguished from those which are toxic or
ineffective.
For other areas like cosmetics, the term MoS  is used quite dif-
ferently to represent the relationship between the estimated or
measured Systemic-Exposure-Dose (SED) for the exposed person
and the NOAEL/NOAEC determined in appropriate animal tests.
Usually, the NOAEC represents the highest systemic concentra-
tion for which a test chemical does not induce an adverse effect
in the test animal when exposed repeatedly (e.g. for 90 days) to
that concentration.
In this form the MoS, sometimes known as a Margin of Expo-
sure (MoE), is regularly used in risk-assessment procedures. The
EU Scientiﬁc Committee on Consumer Safety (SCCS, 2012) applies
this MoS  approach regularly to deﬁne the expected level of safety
in the assessment of cosmetic products.
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Besides the estimated or measured exposure dose, the
OAEL/NOAEC has to be measured in animal tests using the most
elevant exposure route (oral, dermal, inhalation). In case of der-
al  or oral exposure both the SED and the NOAEL are given as
mg/kg bw/d]. For inhalation, the NOAEC are typically given as
mg/m3] or [ppm].
oS  = NOAEL (or NOAEC)
SED
(3)
The general assumption is that a MoS  value of at least 100
nsures an appropriate level of safety for systemic exposure from
onsumer products like cosmetics. The same factor is currently
equested by the US EPA for demonstrating chemical safety.
For the safety assessment of spray products, the MoS  calcula-
ion is more complex compared to other applications, in addition
o the dose the physical nature of the particles (e.g. size) will have
 signiﬁcant impact on the exposure as explained before. Finally,
echnical details determine where exposure occurs in the respira-
ory tract (see Fig. 1; different cell types in the different regions of
he respiratory tract may  be affected uniquely). As both, the site of
xposure and the particle/droplet size inﬂuence the local exposure
mg/cm2 lung tissue], a risk assessment based on a “simple” MoS
alculation may  not be appropriate.
Speciﬁc exposure data for certain areas in the respiratory tract
nd appropriate information (dose–response-relationship) on both
ystemic and local effects from standard toxicity tests are useful in
 proper risk assessment of sprayed products.
. Discussion
Products and in particular, consumer products have to be safe
nder conditions of foreseeable use as required by numerous reg-
lations. Consequently, it is important to agree on the key data
eeded for an informed and representative risk assessment. Dur-
ng the last few decades, both industry partners and regulators have
uilt expertise in the risk assessment of consumer products which
ome into contact with the skin or could be occasionally ingested.
or spray products, a risk assessment is essentially more complex,
ue to the number of variables inﬂuencing the exposure as well
s the nature of the particles/droplets released during a spraying
vent.
For uptake via the inhalation route, the particle/droplet sizes
nd velocity dictate if exposure will be mainly local sedimentation
n the upper respiratory tract or diffusion in the alveolar region.
he size of particle/droplets and velocity of a spray is inﬂuenced
y technical details such as the pressure in the spray can, the can
ize and even the geometry of the spray nozzle. In addition, prod-
ct composition such as propellant and solvent use may  trigger an
xposure episode in particular areas of the respiratory tract. As the
nal exposure scenario is sensitive to all the above parameters, and
s often not comparable to the exposure scenario used in standard
nhalation toxicity studies (e.g. OECD #413), a more appropriate
xposure characterization is necessary for a robust and reliable risk
ssessment.
. Conclusion
This review summarizes current best practices on how to eval-
ate the risk of inhaled ingredients from spray products. Using
 tiered approach, based on consideration of exposure, the dis-
ussed evaluation strategy is useful and appropriate in providing
 robust risk assessment for both the consumer and the occupa-
ional use of spray products. The particular requirements of the
arious regulatory bodies involved in the safety evaluations of spray
roducts have been described. This should enable companies and
gencies to prepare risk assessments for spray products with anetters 227 (2014) 41–49
approach relevant to the level of concern. This could be based on
modelling exposure for the particular formulation and application
scenario, or at a higher tier, to measure real exposure under simu-
lated use conditions for a more accurate exposure characterization.
The introduced ranked hierarchy of approaches will be useful to
better ensure safety of spray products.
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